Sun Pharmaceuticals introduced FluGuard® (Favipiravir 200 mg) today at the price of Rs. 35/tablet which will treat mild to moderate COVID-19 cases.
Favipiravir is approved in India to use as oral anti viral and defined severity in the COVID-19.
Kirti Ganorkar, CEO of India Business, Sun Pharma commented on the occasion of the launch, “With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching FluGuard® at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden. This is in line with our continuous efforts to support India’s pandemic response.”
The company will work closely with the government and medical community to ensure the availability of FluGuard® to patients across the country. The stocks of FluGuard® will be available in the market from this week.
